Grupo para la caracterización molecular de las neoplasias hematológicas
Hospital Severo Ochoa
Madrid, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Severo Ochoa (21)
2024
-
COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant
Cancers, Vol. 16, Núm. 2
-
Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)
Scientific Reports
2023
-
COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
Cancers, Vol. 15, Núm. 5
-
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4
Haematologica, Vol. 108, Núm. 1, pp. 34-41
2022
-
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Scientific Reports, Vol. 12, Núm. 1
-
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group
Disease markers, Vol. 2022, pp. 3132941
2020
-
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study
Journal of Hematology and Oncology, Vol. 13, Núm. 1
-
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
Blood Cancer Journal, Vol. 10, Núm. 10
2017
2015
2014
-
Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?
American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211
2013
-
Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma: Results from a GEM/PETHEMA study
British Journal of Haematology, Vol. 163, Núm. 5, pp. 581-589
2012
-
Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases
Journal of Crohn's and Colitis, Vol. 6, Núm. 5, pp. 518-523
2011
-
Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: Toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03)
Leukemia and Lymphoma, Vol. 52, Núm. 3, pp. 409-416
-
Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab
Expert Review of Hematology, Vol. 4, Núm. 1, pp. 9-16
-
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy
Haematologica, Vol. 96, Núm. 10, pp. 1470-1477
-
Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma
Leukemia Research, Vol. 35, Núm. 4, pp. 431-437
2009
-
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide
Leukemia and Lymphoma, Vol. 50, Núm. 8, pp. 1283-1289
1999
-
Alteraciones tiroideas asociadas al tratamiento con interferon en pacientes con hepatitis cronica viral o esclerosis multiple
Medicina Clinica, Vol. 113, Núm. 2, pp. 50-51
1992
-
Antro retenido, diagnóstico endoscópico y significación clínica.
Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 81, Núm. 3, pp. 200-203